AbbVie stock holds firm after Q2 revenue beat
Published on 08/19/2026 at 07:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
AbbVie Inc. (US00287Y1091) closed at $258.77 on August 18, 2026, after a 3.36% move and a market value of $457.34 billion. The company also reported Q2 2026 revenue of $16.99 billion and adjusted EPS of $3.65, both above estimates in the latest earnings flash.
Q2 numbers stay central
The second quarter gave investors two hard comparison points: revenue rose 10% year over year to $16.99 billion, and adjusted EPS increased 23% to $3.65. Those figures matter because they sit against a 2026 EPS outlook of $13.87 to $14.07, which was also reported with the quarter.
Skyrizi and Rinvoq remain the main growth engines in the reported quarter, while Humira continued to offset part of that momentum. The mix matters more than the headline alone: AbbVie is still proving it can replace older revenue with newer immunology and neuroscience products.
Guidance and valuation
Analyst consensus on the name remains constructive, with one market consensus page showing a BUY view and a last close price of $258.92 alongside an average target price framework. That puts the stock close to its recent trading range, where one market data page showed $258.92 within a 52-week band of $190.75 to $267.47.
The valuation debate is now more visible than the earnings beat itself. A stock that has already added 9.57% this year needs continued execution, and AbbVie has delivered that through Q2 2026 revenue of $16.99 billion and adjusted EPS of $3.65.
Immunology support
AbbVie also said 34 students will receive its 2026 Immunology Scholarship, which marks the program's 10th year. The initiative is small next to the quarterly numbers, but it reinforces the company's long-running connection to immunology, the franchise that still drives the investment story.
AbbVie drug mix
Skyrizi and Rinvoq are the products that matter most to the current growth mix, because they sit at the center of the company's immunology expansion. Their combined strength is what makes the $16.99 billion quarter more than a one-off result.
Shares and context
AbbVie stock ended the most recent session at $258.77, with the market cap at $457.34 billion and the year-to-date move at 9.57%. The next reported earnings date should be read from the company schedule if it is set for the future.
Fact box
Company: AbbVie Inc.
ISIN: US00287Y1091
Ticker: ABBV
Exchange: NYSE
Price (as of August 18, 2026, 4:00 p.m. ET): $258.77 USD
Market cap: $457.34 billion (as of August 18, 2026)
Sector / Industry: Health Care / Pharmaceuticals
Index membership: S&P 500
More on AbbVie stock
AbbVie's main product mix still leans on immunology, with Skyrizi and Rinvoq carrying the growth burden in Q2 2026 while Humira fades. That makes the current quarter's $16.99 billion in revenue and $3.65 in adjusted EPS the key reference points for the stock.
